Alphatec (NASDAQ:ATEC) EVP Sells $410,616.44 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig Hunsaker sold 33,602 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $12.22, for a total value of $410,616.44. Following the completion of the transaction, the executive vice president owned 1,808,974 shares of the company’s stock, valued at $22,105,662.28. The trade was a 1.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $12.50 on Friday. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.28 and a current ratio of 2.06. Alphatec Holdings, Inc. has a one year low of $8.81 and a one year high of $23.29. The firm has a market capitalization of $1.89 billion, a P/E ratio of -13.16 and a beta of 1.02. The company’s fifty day moving average is $15.28 and its two-hundred day moving average is $16.90.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $212.93 million during the quarter, compared to analysts’ expectations of $212.67 million. During the same quarter in the prior year, the business earned ($0.23) EPS. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. Analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Trading of Alphatec

Several hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Alphatec by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company’s stock worth $750,000 after purchasing an additional 3,196 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Alphatec in the first quarter valued at $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Alphatec by 18.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company’s stock worth $2,696,000 after buying an additional 41,264 shares during the period. Teacher Retirement System of Texas boosted its stake in Alphatec by 12.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 17,447 shares of the medical technology company’s stock worth $194,000 after buying an additional 1,912 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in Alphatec by 545.7% in the 2nd quarter. Bank of Montreal Can now owns 743,041 shares of the medical technology company’s stock worth $8,248,000 after buying an additional 627,973 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ATEC shares. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Alphatec in a research report on Monday, January 12th. Morgan Stanley set a $23.00 price target on Alphatec in a report on Tuesday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Alphatec in a research note on Monday, January 12th. TD Cowen reaffirmed a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Finally, Lake Street Capital reissued a “buy” rating on shares of Alphatec in a report on Wednesday, February 25th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.82.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.